Neoadjuvant chemotherapy of breast cancer

American Surgeon

Volumn 70, Issue 7, 2004, Pages 565-569

  Garces, Christopher A ^a   Cance, William G ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; CYCLOPHOSPHAMIDE; DOXORUBICIN; TAXANE; TAXOID;

ADJUVANT CHEMOTHERAPY; ANIMAL; ANIMAL MODEL; BREAST TUMOR; CLINICAL TRIAL; FEMALE; HUMAN; MOUSE; REVIEW;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; MICE; MODELS, ANIMAL; TAXOIDS;

EID: 3843093888     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. Veronesi U, Saccozzi R, Del Vecchio M, et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med 1981;305:6-11. (Pubitemid 11071189)
2. Fisher B, Bauer M, Margolese R, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 1985;312:665-673 (Pubitemid 15134702)
3. Fisher B, Jeong JH, Anderson S, et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002;347:567-575 (Pubitemid 34898869)
4. Bonadonna G. Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res 1992;52:2127-2137
5. Schabel FM Jr. Concepts for treatment of micrometastases developed in murine systems. Am J Roentgenol 1976;126:500-511
6. Griswold DP Jr, Corbett TH. Breast tumor modeling for prognosis and treatment. Recent Results Cancer Res 1976;(57):42-58.
7. Corbett TH, Griswold DP Jr, Roberts BJ, et al. Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy. Cancer Treat Rep 1978;62:1471-1488
8. Simpson-Herren L, Sanford AH, Holmquist JP. Effects of surgery on the cell kinetics of residual tumor. Cancer Treat Rep 1976;60:1749-1760
9. Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 1983;43:1488-1492
10. Gunduz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res 1979;39:3861-3865
11. Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976;294:405-410
12. Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995;332:901-906
13. Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 1995;273:542-547
14. Bonadonna G, De Lena M, Brambilla C, et al. Combination chemotherapy and combined treatment modality in disseminated and locally advanced breast cancer. Prog Clin Biol Res 1977;12:437-458
15. De Lena M, Zucali R, Viganotti G, et al. Combined chemotherapy- radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol 1978;1:53-59 (Pubitemid 9025112)
16. Bonadonna G, Valagussa P, Zucali R, et al. Primary chemotherapy in surgically resectable breast cancer. CA Cancer J Clin 1995;45:227-243
17. Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998;16:93-100. (Pubitemid 28041584)
18. Hortobagyi GN, Spanos W, Montague ED, et al. Treatment of locoregionally advanced breast cancer with surgery, radiotherapy, and combination chemoimmunotherapy. Int J Radiat Oncol Biol Phys 1983;9:643-650
19. Hortobagyi GN, Gutterman JU, Blumenschein GR, et al. Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. Cancer 1979;43:1225-1233 (Pubitemid 9180288)
20. Hortobagyi GN, Frye D, Buzdar AU, et al. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer 1989;63:37-45. (Pubitemid 19031978)
21. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-469
22. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483-2493 (Pubitemid 27289876)
23. Cance WG, Carey LA, Calvo BF, et al. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. Ann Surg 2002;236:295-302; discussion 302-303
24. Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 1997;89:917-931 (Pubitemid 27282064)
25. Ravdin PM. Anthracycline resistance in breast cancer: clinical applications of current knowledge. Eur J Cancer 1995;31A(Suppl 7):S11-4.
26. Kaye SB. Multidrug resistance in breast cancer - is the jury in yet? J Natl Cancer Inst 1997;89:902-903
27. Nabholtz JM, Crown J. Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results. Semin Oncol 1998;25(6 Suppl 13):4-9. (Pubitemid 28564176)
28. Clemons M, Leahy M, Valle J, et al. Review of recent trials of chemotherapy for advanced breast cancer: the taxanes. Eur J Cancer 1997;33:2183-2193 (Pubitemid 28123408)
29. Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995;13:2886-2894
30. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003;21:4165-4174 (Pubitemid 46606185)
31. Newman LA, Buzdar AU, Singletary SE, et al. A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility. Ann Surg Oncol 2002;9:228-234
32. Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002;20:1456-1466
33. Hutcheon AW, Heys SD, Sarkar TK. Neoadjuvant docetaxel in locally advanced breast cancer. Breast Cancer Res Treat 2003;79(Suppl 1):S19-24.
34. Nason KS, Anderson BO, Byrd DR, et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer 2000;89:2187-2194
35. Breslin TM, Cohen L, Sahin A, et al. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2000;18:3480-3486 (Pubitemid 30783326)
36. van der Hage JA, van de Velde CJ, Julien JP, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001;19:4224-4237